Assembly biosciences presents interim phase 1b data for hsv helicase-primase inhibitor candidate abi-5366 at the 38th congress of the international union against sexually transmitted infections (iusti)- europe

– late-breaking oral presentation highlights interim phase 1b data reported earlier this year for two cohorts in participants with recurrent genital herpes –  – statistically significant reductions in hsv-2 shedding rate, high viral load shedding rate and genital lesion rate observed in the cohort evaluating 350 mg weekly oral dose compared to placebo – – interim data evaluating a monthly dosing regimen of abi-5366 and weekly dosing for second hsv helicase-primase inhibitor candidate abi-1179 expected to be shared later this fall – south san francisco, calif., oct. 10, 2025 (globe newswire) -- assembly biosciences, inc. (nasdaq: asmb), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that interim phase 1b clinical data for its long-acting herpes simplex virus (hsv) helicase-primase inhibitor candidate abi-5366 are featured in a late-breaking oral presentation during the 38th congress of the international union against sexually transmitted infections (iusti)- europe, taking place october 9-11, 2025, in athens, greece.
ASMB Ratings Summary
ASMB Quant Ranking